Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572730 | 0.90 | MAPT (0.60) | THRBMAPTTAS2R14ALDH1A1MEN1 | |
| SCHEMBL5570733 | 0.89 | ALDH1A1 (0.60) | THRBMAPTCA12CA1CA9 | |
| SCHEMBL5572753 | 0.86 | SMN1; SMN2 (0.55) | CA12CA1CA9ALDH1A1MEN1 | |
| SCHEMBL5573330 | 0.84 | MEN1 (0.58) | THRBMAPTCA12CA1CA9 | |
| SCHEMBL5569737 | 0.84 | CA12 (0.50) | THRBCA12CA1CA9ALDH1A1 | |
| SCHEMBL7372107 | 0.82 | THRB (0.44) | THRBMAPTCA12CA1CA9 | |
| SCHEMBL7372105 | 0.82 | THRB (0.44) | THRBMAPTCA12CA1CA9 | |
| SCHEMBL5191217 | 0.79 | TAS2R14 (0.71) | THRBMAPTTAS2R14ALDH1A1MEN1 | |
| SCHEMBL30699961 | 0.78 | CA1 (0.54) | CA12CA1CA9MEN1LMNA | |
| SCHEMBL15705617 | 0.77 | MAPT (0.65) | THRBMAPTTAS2R14ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | claimed |
| US-7166580-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN MA INC. | 2003-09-04 | — | — | US | disclosed |
| US-6559127-B1 | Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166575-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | THRB 1737/4885MAPT 816/4885CA12 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.